Contraindications to Upatinib use in patients

Upadacitinib is a selective JAK1 inhibitor mainly used to treat immune-related diseases such as rheumatoid arthritis and atopic dermatitis. Although upadatinib has shown significant efficacy in these diseases, there are some contraindications and special precautions during its use. Patients need to strictly follow the doctor's instructions to ensure the safety of the medication. The following are the main contraindications of upadatinib:

1. Those who are allergic to upadatinib and its ingredients

Any patient who is allergic to upadacitinib or its excipients should avoid using this drug. Allergic reactions may manifest as rash, itching, difficulty breathing and other symptoms. Once such symptoms occur, patients should stop taking the medication and seek medical advice immediately.

2. Patients with active severe infection

In the process of inhibiting JAK1, upadatinib may also have a certain inhibitory effect on the immune system, thereby increasing the risk of infection. Therefore, patients with active serious infections (such as active tuberculosis, sepsis, pneumonia, or other bacterial, viral, fungal infections) should not use upadacitinib. For patients with potential infection risks, doctors will evaluate them before treatment and may recommend delaying medication until the infection is effectively controlled.

3. Patients with a past history of tuberculosis

Special caution is required before using upadatinib in patients with a past history of tuberculosis. Although such patients can be treated under the supervision of a doctor, they must first undergo a TB screening to ensure that TB is inactive. In addition, prophylactic antituberculosis drugs may need to be given concurrently with treatment to reduce the risk of relapse.

4. Persons with severe liver function impairment

Upapatinib is primarily metabolized in the liver; therefore, upapatinib should be used with special caution in patients with severe hepatic impairment. Taking this drug in such patients may result in elevated blood drug concentrations, thereby increasing the risk of adverse reactions. For patients with moderate or mild liver impairment, doctors may adjust the dose or adopt other treatment options based on the specific situation.

5. Pregnant and lactating women

Upapatinib is not recommended for use in pregnant or lactating women because there are currently insufficient clinical data to confirm its safety during pregnancy or lactation. Studies have shown that JAK1 inhibitors may affect fetal growth and development. Therefore, women planning to become pregnant should discuss the risks of the drug in detail with their doctors before using upadatinib. In addition, breastfeeding is not recommended while taking this drug to prevent the drug from affecting the baby through breast milk.

6. Patients with thrombotic diseases

After using upadacitinib, some patients may have a tendency to increase the risk of thrombotic events (such as venous thrombosis, pulmonary embolism, deep vein thrombosis, etc.). For patients with a history of thrombosis, such as deep vein thrombosis, arterial embolism, etc., a risk assessment needs to be conducted and preventive measures must be taken before using this drug. Your doctor may weigh the benefits and risks of treatment and decide whether continued use is appropriate.

7. Patients with immunosuppressive diseases

Due to the regulatory effect of upadatinib on the immune system, patients with other immunosuppressive diseases (such as AIDS, tumors, etc.) need to be particularly careful when using this drug. The use of immunosuppressants in these patients may increase the risk of infection, and they need to be treated under strict supervision by doctors, and the dosage and medication regimen must be adjusted.

8. Severe renal insufficiency

Upadatinib should also be used with caution in patients with severe renal insufficiency. Renal insufficiency will affect the excretion process of drugs, leading to increased blood drug concentrations and increasing the risk of side effects. Such patients need to regularly detect renal function indicators during treatment and make adjustments under the guidance of a doctor.

9. Patients with a history of cancer

Upapatinib may increase the risk of certain types of tumors, especially with long-term use. Therefore, patients with a history of cancer, such as malignant lymphoma, skin cancer, etc., need to be particularly careful when using this drug. Doctors will decide whether it is appropriate to continue treatment based on individual circumstances and conduct regular examinations and monitoring during treatment.

Upadatinib has significant efficacy in the treatment of immune diseases such as rheumatoid arthritis and atopic dermatitis, but there are some contraindications during use. Patients should understand their own conditions in detail before use to avoid serious adverse reactions caused by inappropriate medication. Following the doctor's medication recommendations and regular review are the keys to ensuring medication safety and efficacy. Through careful medication management, patients can better control their condition during treatment while reducing medication risks.